News & Articles

Company exploring further additional global capacity to provide broad and equitable access

llumina's COVIDSeq aims to generate information about the genomic sequence of the virus

Large-scale manufacturing of rapid diagnostic test kit and reagents to enable increased testing capacity for COVID-19 worldwide

The RECOVERY trial has shown that hydroxychloroquine is not an effective treatment in patients hospitalized with COVID-19

Total antibody test aims to deliver superior clinical performance with 100% sensitivity and 99.8% specificity

The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients

A rare lung disease drug is being trialed to help fight COVID-19

The study is expected to begin enrolling in June with a target of approximately 450 patients globally

Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels

The RNAdvance Viral XP is a RNA extraction kit validated for use in infectious disease and real-time PCR virus research

The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial COV002 by the University of Oxford

First patients are expected to be enrolled shortly and additional European regulatory approvals are in process

People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus

Cambridge Cognition has secured over $1.5 million in new contracts to support pharmaceutical clients in delivering virtual clinical trials

Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity

Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers

Study suggests that type I IFN deficiency in the blood could help define a high-risk population

The COVID-19 vaccine trial is part of a global development program that will uncover the safety and immunogenicity of four mRNA vaccine candidates.

The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S

AMSBIO's new service utilizes their novel lentiviral system to aid the development of therapeutic drugs and vaccines

The U.S. Food and Drug Administration has approved Tabrecta (capmatinib) to treat adult patients with non-small cell lung cancer

Preliminary results from a government-sponsored study suggest that drug used to treat Ebola may help COVID-19 patients

Innovosens building partnerships to accelerate development, testing and market launch